Comparative analysis between the two groups revealed that patients in the metastatic prostate cancer group had higher SII, neutrophil count, monocyte count, and PSA levels compared to the localized prostate cancer group. The gene discussed is KLK3; the disease is metastatic prostate carcinoma.